Evidence map›Paper›PMID 41203805›Full record

ArticleCommunications chemistry2025

Ultra-large library screening with an evolutionary algorithm in Rosetta (REvoLd).

Paul Eisenhuth, Fabian Liessmann, Rocco Moretti, Jens Meiler

Abstract read
In one paragraph

Article in Communications chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. A General Group Testing Strategy for Discovering Chemical Cooperativity.Angewandte Chemie (International ed. in English) · 2026
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Paul EisenhuthInstitute for Drug Discovery, Leipzig University, Leipzig, Germany. eisenhuth@cs.uni-leipzig.de.ORCID http://orcid.org/0009-0006-7379-5096
Fabian LiessmannInstitute for Drug Discovery, Leipzig University, Leipzig, Germany.ORCID http://orcid.org/0009-0007-9199-1629
Rocco MorettiCenter for Structural Biology, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-2162-1116
Jens MeilerInstitute for Drug Discovery, Leipzig University, Leipzig, Germany.

Funding

Decrypting Variants of Uncertain Significance in Long-QT SyndromeR01HL122010 · NHLBI · VANDERBILT UNIVERSITY · PI GEORGE, ALFRED L., SANDERS, CHARLES R · 2014 to 2025
$15.5M
Membrane Protein Structure Elucidation from sparse NMR data (KAMP)R01GM080403 · NIGMS · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2007 to 2019
$3.0M
Structural Determinants of Allosteric Modulation of Brain GPCRsR01DA046138 · NIDA · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2019 to 2023
$2.0M
Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) ScaDS.AIDeutsche Forschungsgemeinschaft (German Research Foundation) SFB1423 (421152132)Deutsche Forschungsgemeinschaft (German Research Foundation) SPP2363 (460865652)NHLBI NIH HHS R01 HL122010NIDA NIH HHS R01 DA046138NIGMS NIH HHS R01 GM080403
6 · The paper itself

Abstract

Ultra-large make-on-demand compound libraries now contain billions of readily available compounds. This represents a golden opportunity for in-silico drug discovery. One challenge, however, is the time and computational cost of an exhaustive screen of such large libraries when receptor flexibility is taken into account. We propose an evolutionary algorithm to search combinatorial make-on-demand chemical space efficiently without enumerating all molecules. We exploit the feature of make-on-demand compound libraries, namely that they are constructed from lists of substrates and chemical reactions. Our algorithm RosettaEvolutionaryLigand (REvoLd) explores the vast search space of combinatorial libraries for protein-ligand docking with full ligand and receptor flexibility through RosettaLigand. A benchmark of REvoLd on five drug targets showed improvements in hit rates by factors between 869 and 1622 compared to random selections. REvoLd is available as an application within the Rosetta software suite ( https://docs.rosettacommons.org/docs/latest/revold ). This work formulates an evolutionary algorithm for optimization and exploration of ultra-large make-on-demand libraries. We demonstrate that our approach results in strong and stable enrichment, offering the most efficient algorithm for drug discovery in ultra-large chemical space to date.

Identifiers

PMID41203805
PMCPMC12594993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.